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X-linked hypophosphatemic rickets: a new mutation
Raquitismo hipofosfatêmico ligado ao X: uma nova mutação
O raquitismo fosfopênico pode ser causado 
por mutações no gene PHEX (ligado ao 
X do homólogo da endopeptidase que 
regula o fosfato). Atualmente, mais de 
500 mutações no gene PHEX causam 
raquitismo hipofosfatêmico. Os autores 
relatam um caso clínico de uma menina de 
4 anos com histórico familiar sem relevância, 
que apresentou falha no crescimento 
e arqueamento das pernas. Os exames 
laboratoriais mostraram hipofosfatemia, 
fosfatase alcalina elevada, cálcio normal, 
PTH levemente elevado e níveis normais 
de 25(OH)D e 1,25(OH)D. O estudo 
radiológico mostrou deformidades ósseas 
no rádio e no fêmur. O diagnóstico clínico 
do raquitismo fosfopênico foi realizado e 
o estudo genético detectou uma provável 
variante patogênica heterozigótica do gene 
PHEX: c.767_768del (p.Thr256Serfs*7). 
Esta variante não foi descrita anteriormente 
na literatura ou nas bases de dados. 
O conhecimento sobre novas mutações 
pode melhorar o desfecho de pacientes. A 
análise genética pode ajudar a estabelecer 
uma correlação genótipo-fenótipo.
Resumo
Descritores: Raquitismo hipofosfatêmico; 
Mutação; PHEX.
Phosphopenic rickets may be caused by 
mutations in the PHEX gene (phosphate 
regulating endopeptidase homolog 
X-linked). Presently, more than 500 
mutations in the PHEX gene have been 
found to cause hypophosphatemic rickets. 
The authors report a clinical case of a 
4-year-old girl with unremarkable family 
history, who presented with failure to 
thrive and bowing of the legs. Laboratory 
tests showed hypophosphatemia, 
elevated alkaline phosphatase, normal 
calcium, mildly elevated PTH and normal 
levels of 25(OH)D and 1.25(OH)D. 
The radiological study showed bone 
deformities of the radius and femur. 
Clinical diagnosis of phosphopenic 
rickets was made and the genetic study 
detected a heterozygous likely pathogenic 
variant of the PHEX gene: c.767_768del 
(p.Thr256Serfs*7). This variant was not 
previously described in the literature 
or databases. Knowledge about new 
mutations can improve patient’s outcome. 
Genetic analysis can help to establish a 
genotype-phenotype correlation.
AbstRAct





Phosphopenic rickets occurs as a result 
of inherited or acquired abnormalities in the 
proximal tubular handling of phosphorus1. 
X-linked hypophosphatemic rickets (XLH) 
is the most common inherited form of rickets 
with an incidence of 1:20,000 individuals2-5. 
This disorder is caused by inactivating 
pathogenic variants in PHEX gene 
(Phosphate regulating Endopeptidase homolog 
X-linked), which is located on chromosome 
locus Xp22.1 and contains 22 exons6. 
These inactivating variants result in excess 
circulating FGF-23 (fibroblast growth 
factor 23), that impairs renal phosphate 
reabsorption on proximal tubule cells via 
FGFR1 (fibroblast growth receptor 1) and 
its co-receptor KLOTHO.
Although XLH rickets is inherited in 
an X-linked dominant way, the severity 
of its manifestations is variable. The 
diagnosis of XLH is suspected based 
on clinical manifestations, laboratory 
abnormalities, and X-ray findings. 
Braz. J. Nephrol. (J. Bras. Nefrol.) 2020. Ahead of print
X-linked hypophosphatemic rickets
2
It can be confirmed by the identification of a 
hemizygous (in males) or heterozygous (in females) 
pathogenic variant in PHEX by molecular genetic 
testing7,8. A positive family history can facilitate the 
diagnosis, but de novo mutations occur frequently8.
Clinical manifestations include growth retardation, 
abnormal bone mineralization, osteomalacia, bone 
pain, and deformity of the lower limbs (genu varus 
or valgus)7,9. Usually the birth length is normal, 
but the growth rate slows in infancy7. The clinical 
manifestations often become apparent in the first 
two years of life, especially when the child begins to 
walk, causing bowing of the legs and short stature.
Affected individuals may present dental 
malposition and periradicular abscesses due to 
defective dentin or enlarged pulp chambers and root 
canals10. Premature cranial synostosis can occur 
with dolichocephaly, parietal flattening, and frontal 
bossing8,11,12. Adults may present pseudofractures, 
osteoarthritis, osteophytes, or enthesopathy.
Laboratory findings include hypophosphatemia 
with hyperphosphaturia, normal serum calcium 
levels, normal or reduced calciuria, and normal 25 - 
(OH) – vitamin D levels. The serum levels of PTH 
are normal or mildly elevated, and plasmatic alkaline 
phosphatase is increased. There is resistance to high 
doses of vitamin D13. High serum levels of FGF-23 
can be found10.
X-ray findings include deformities of the lower 
limb and widened, frayed, or cupped metaphyses7. 
In adult patients, calcifications of the tendons or 
ligaments can be present7.
In this report, we describe a patient with 
hypophosphatemic rickets as result of a novel likely 
pathogenic variant in PHEX gene.
cAse descRIptIon
A 4-year-old female, with unremarkable family 
history, born at full term with adequate weight 
and length, presented with failure to thrive since 
the first year of life (height at the 5th centile until 2 
years old, and at the age of four below 5th centile). 
Leg bowing was noted by the age of 18 months. 
On physical examination, she had frontal bossing, 
hyperlordosis, bowed legs (bilateral genu varum), 
thickened wrists, normal teeth and hair (Figure 1). 
No complaints of muscle pain were referred.
Figure 1. Proband at 4 years of age, presenting with bowed legs, 
bilateral genu varum, and enlarged wrists.
Blood workup showed hypophosphatemia (2.4 
mg/dL), elevated alkaline phosphatase (495 U/L), 
normal calcemia, mildly elevated PTH (97.2 pg/mL; 
RR <68.3), and normal levels of 25-(OH)-vitamin D 
and 1.25-(OH)-vitamin D. The radiological evaluation 
showed bone deformities of the radius and femur.
As the diagnosis of phosphopenic rickets was 
made, she started treatment with calcitriol 125 mcg/
day and phosphorus 2500 mg/day.
Currently, at 11 years old, the patient has no 
clinical or radiographic signs of rickets. Bone age is in 
agreement with the chronological age and there was 
a considerable increase in growth rate (15th centile), 
which corresponds to her target height (Figure 2). Renal 
ultrasound shows incipient signs of nephrocalcinosis 
since the age of nine. Blood workup shows PTH 53.20 
pg/mL, alkaline phosphatase 291 U/L, phosphatemia 
2.7 mg/dL, and calcemia 10.2 mg/dL.
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The genetic analysis detected a heterozygous 
likely pathogenic variant of the PHEX gene: variant 
c.767_768del (p.Thr256Serfs*7). This variant was 
not previously described in literature or databases. 
However, since it introduces a premature stop codon 
resulting in a truncated protein, which is a known 
mutational mechanism of XLH, this is very likely to 
be a pathogenic variant. The parent’s genetic study is 
still in progress.
dIscussIon
The authors report the case of a girl with clinical, 
biochemical, and radiologic findings of phosphopenic 
rickets. The patient received treatment with 
phosphorus and calcitriol with growth improvement. 
The genetic study identified a novel likely pathogenic 
variant in PHEX gene, which produces a premature 
stop codon, resulting in a truncated protein.
A PHEX gene pathogenic variant was first 
described in 199514. Presently, more than 500 
pathogenic variants in this gene have been reported to 
cause XLH (HGMD professional 2019.4). Different 
gene defects including missence, nonsense, splice 
site, small and gross deletions, and insertions have 
been described in the literature, in the Human Gene 
Mutation Database, and in the PHEX mutation 
database15.
The PHEX gene encodes a membrane-bound 
endopeptidase that is expressed at the cell-surface 
membrane of osteoblast, osteocytes, odontoblasts, lung, 
liver, muscle and gonads7,10. PHEX pathogenic variants 
increase the production of FGF-23, which promotes 
a phosphaturic effect, leading to hypophosphatemia. 
Despite that, the pathophysiologic mechanism through 
which the PHEX loss of function variants increase the 
levels of FGF-23 is not fully understood7.
In patients with XLH, the renal phosphate wasting 
should be evaluated by calculating the tubular 
maximum reabsorption of phosphate per glomerular 
filtration rate (TmP/GFR)13.
Conventional treatment of children with 
hypophosphatemic rickets includes a combination 
of oral doses of phosphate preparations (four to five 
times a day) and active vitamin D analogs (calcitriol 
or alfacalcidol)10. Goals of treatment also include 
normalization of alkaline phosphatase and trying 
to maintain calciuria in the normal range, to avoid 
calcium deposition in the renal parenchyma; however, 
normalization of serum levels of phosphate is not a 
goal of conventional therapy, as it would be difficult to 
achieve and would also promote nephrocalcinosis10,13. 
In this report, the patient present incipient signs 
of nephrocalcinosis since the age of nine. This 
adverse effect of treatment has been controlled with 
kidney ultrasonography and adjustments of therapy 
avoiding large doses of phosphate supplements and 
keeping normal calciuria levels. If necessary, the use 
of potassium citrate can help to prevent calcium 
precipitation, but it increases the risk of phosphate 
precipitation. Therefore, potassium citrate should be 
used with caution13. The therapy with burosumab 
should be considered if nephrocalcinosis worsens.
burosumab (Crysvita®), a fully human 
recombinant IgG1 monoclonal antibody directed at 
fibroblast growth factor 23 (FGF23) was approved by 
the European Medicines Agency (EMA) in February 
2018 for the treatment of XLH with radiologic bone 
disease in children ≥1 year of age and in adolescents 
with a growing skeleton. It has also been approved by 
the US Food and Drug Administration (FDA) in April 
2018 for the treatment of XLH in adults and children 
≥1 year13,16.  The starting dose is 0.4 mg/kg, with a 
maintenance dose of 0.8 mg/kg (up to a maximum 
dose of 90 mg) administered as a subcutaneous 
therapy once every 2 weeks16. 
The decision to approve burosumab to 
treat XLH in adults and children were based 
in the results of several trials. Two open-label 
uncontrolled trials testing burosumab in 65 children 
aged 1–12 years with severe XLH demonstrated 
that in 12–16 months burosumab resulted in a 
statistically significant increase in TmP/GFR, 
with subsequent higher serum phosphate levels, higher 
Figure 2. Evolution of the patient’s height.
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1,25(OH)2 vitamin D levels, a significant reduction in 
the severity of rickets, a remarkable improvement in 
physical ability, and a significant reduction in patient-
reported pain and functional disability13.
In this case, burosumab was considered but 
postponed due to the successful response to 
conventional therapy.
In conclusion we report a novel, likely pathogenic, 
variant in PHEX gene in a girl with clinical, laboratory, 
and radiological findings of rickets. Genetic diagnosis 
is extremely important as it may determine precise 
treatment decisions and enable genetic counselling 
and genetic prenatal diagnosis17. Knowledge about the 
mutational spectrum of genetic diseases is important 
for better genotypic characterization and can improve 
the patient’s outcome. Genetic analysis can help to 
establish a genotype-phenotype correlation13.
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